JP2023126934A - 肺癌を検出するためのバイオマーカーパネル - Google Patents
肺癌を検出するためのバイオマーカーパネル Download PDFInfo
- Publication number
- JP2023126934A JP2023126934A JP2023111262A JP2023111262A JP2023126934A JP 2023126934 A JP2023126934 A JP 2023126934A JP 2023111262 A JP2023111262 A JP 2023111262A JP 2023111262 A JP2023111262 A JP 2023111262A JP 2023126934 A JP2023126934 A JP 2023126934A
- Authority
- JP
- Japan
- Prior art keywords
- lung cancer
- serum
- analysis
- biomarker
- metabolites
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000090 biomarker Substances 0.000 title claims abstract description 65
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims abstract description 57
- 201000005202 lung cancer Diseases 0.000 title claims abstract description 57
- 208000020816 lung neoplasm Diseases 0.000 title claims abstract description 57
- 210000002966 serum Anatomy 0.000 claims abstract description 53
- -1 C10:2 Substances 0.000 claims abstract description 9
- NQNXERHVLXYXRO-UHFFFAOYSA-N Diacetylspermine Chemical compound Cl.Cl.CC(=O)NCCCNCCCCNCCCNC(C)=O NQNXERHVLXYXRO-UHFFFAOYSA-N 0.000 claims abstract description 8
- LRKATBAZQAWAGV-UHFFFAOYSA-N Hexatriacontylic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC(O)=O LRKATBAZQAWAGV-UHFFFAOYSA-N 0.000 claims abstract description 7
- CEZAZXUWDFPTTE-FHIJIHMSSA-N PC(O-22:2(13Z,16Z)/22:3(10Z,13Z,16Z)) Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCCCCCOC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC\C=C/C\C=C/C\C=C/CCCCC CEZAZXUWDFPTTE-FHIJIHMSSA-N 0.000 claims abstract description 5
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 claims description 18
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 claims description 14
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 9
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 9
- 229940063675 spermine Drugs 0.000 claims description 9
- 239000004474 valine Substances 0.000 claims description 9
- YDGMGEXADBMOMJ-UHFFFAOYSA-N asymmetrical dimethylarginine Natural products CN(C)C(N)=NCCCC(N)C(O)=O YDGMGEXADBMOMJ-UHFFFAOYSA-N 0.000 claims description 8
- YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 claims description 8
- 229940063673 spermidine Drugs 0.000 claims description 7
- 230000002485 urinary effect Effects 0.000 claims description 7
- SPJFYYJXNPEZDW-FTJOPAKQSA-N 1-linoleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C SPJFYYJXNPEZDW-FTJOPAKQSA-N 0.000 claims description 6
- 239000004475 Arginine Substances 0.000 claims description 6
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 6
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 6
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 6
- 229930182817 methionine Natural products 0.000 claims description 6
- 229960003104 ornithine Drugs 0.000 claims description 6
- YDGMGEXADBMOMJ-LURJTMIESA-N N(g)-dimethylarginine Chemical compound CN(C)C(\N)=N\CCC[C@H](N)C(O)=O YDGMGEXADBMOMJ-LURJTMIESA-N 0.000 claims description 5
- 229960004295 valine Drugs 0.000 claims description 4
- 239000002207 metabolite Substances 0.000 abstract description 42
- 210000002700 urine Anatomy 0.000 abstract description 10
- 229920000768 polyamine Polymers 0.000 abstract description 7
- 238000000034 method Methods 0.000 abstract description 6
- 238000004458 analytical method Methods 0.000 description 35
- 238000000926 separation method Methods 0.000 description 13
- 238000000513 principal component analysis Methods 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 238000010239 partial least squares discriminant analysis Methods 0.000 description 9
- 238000004949 mass spectrometry Methods 0.000 description 6
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 6
- WUUGFSXJNOTRMR-IOSLPCCCSA-N 5'-S-methyl-5'-thioadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 WUUGFSXJNOTRMR-IOSLPCCCSA-N 0.000 description 4
- MJLXQSQYKZWZCB-DQFWFXSYSA-N O-linoleyl-L-carnitine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C MJLXQSQYKZWZCB-DQFWFXSYSA-N 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 4
- 229960004452 methionine Drugs 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- NWGZOALPWZDXNG-LURJTMIESA-N (2s)-5-(diaminomethylideneamino)-2-(dimethylamino)pentanoic acid Chemical compound CN(C)[C@H](C(O)=O)CCCNC(N)=N NWGZOALPWZDXNG-LURJTMIESA-N 0.000 description 3
- 102100034274 Diamine acetyltransferase 1 Human genes 0.000 description 3
- 101000641077 Homo sapiens Diamine acetyltransferase 1 Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HVPFXCBJHIIJGS-LURJTMIESA-N N(omega),N'(omega)-dimethyl-L-arginine Chemical compound CN\C(=N/C)NCCC[C@H](N)C(O)=O HVPFXCBJHIIJGS-LURJTMIESA-N 0.000 description 3
- 239000005700 Putrescine Substances 0.000 description 3
- 229960003121 arginine Drugs 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000002552 multiple reaction monitoring Methods 0.000 description 3
- 238000009589 serological test Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000007473 univariate analysis Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 150000002327 glycerophospholipids Chemical class 0.000 description 2
- QKFJKGMPGYROCL-UHFFFAOYSA-N phenyl isothiocyanate Chemical compound S=C=NC1=CC=CC=C1 QKFJKGMPGYROCL-UHFFFAOYSA-N 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- RFZSTXLXYYWMQV-UHFFFAOYSA-N 3-hydroxy-4-oxo-3-[(trimethylazaniumyl)methyl]tridec-5-enoate Chemical compound C(C=CCCCCCCC)(=O)C(O)(C[N+](C)(C)C)CC([O-])=O RFZSTXLXYYWMQV-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- MQTAVJHICJWXBR-UHFFFAOYSA-N N(1)-acetylspermidine Chemical compound CC(=O)NCCCNCCCCN MQTAVJHICJWXBR-UHFFFAOYSA-N 0.000 description 1
- GUNURVWAJRRUAV-UHFFFAOYSA-N N(1)-acetylspermine Chemical compound CC(=O)NCCCNCCCCNCCCN GUNURVWAJRRUAV-UHFFFAOYSA-N 0.000 description 1
- SHDVOJJCEZGPBX-QVDQXJPCSA-N O-(3-hydroxyvaleryl)-L-carnitine Chemical compound CCC(O)CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C SHDVOJJCEZGPBX-QVDQXJPCSA-N 0.000 description 1
- WURBQCVBQNMUQT-OLKPEBQYSA-N O-tiglyl-L-carnitine Chemical compound C\C=C(/C)C(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C WURBQCVBQNMUQT-OLKPEBQYSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229940117953 phenylisothiocyanate Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
- G01N33/6812—Assays for specific amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
Description
代謝産物を、10名の対照患者および化学療法治療を受けている12名の肺癌患者から採取した尿試料においてLC-MS/MSベースのアッセイを用いて検出し、定量した。特に、以下の尿試料中のポリアミン経路代謝産物を検出し、定量した:スペルミジン、スペルミン、メチオニン、プトレシン、メチルチオアデノシン(MTA)、S-アデノシル-L-メチオニン(SAMe)、オルニチン、アルギニン、N-アセチルスペルミン、およびN-アセチルスペルミジン。
代謝産物を、15名の対照患者および31名の肺癌患者(7名の初期癌患者を含む)から採取した尿および血清試料において検出した。試料を、上記のようにダイレクトインジェクション質量分析(MS)および逆相LC-MS/MSを組み合わせて用いて分析した。統計分析を、MetaboAnalyst(www.metaboanalyst.com)およびROCCET(www.roccet.ca)を用いて行った。
代謝産物を、時間T1およびT2において26名の後期肺癌患者および15名の対照患者から採取した血清試料において検出した。特に、以下のポリアミン経路代謝産物を、時間T1およびT2における血清試料において検出し、定量した:バリン、アルギニン、オルニチン、メチオニン、スペルミジン、スペルミン、ジアセチルスペルミン、デカジエニルカルニチン(C10:2)、グリセロリン脂質(PC aa C32:2およびPC ae C36:0)、lysoPC a C18:2、メチルチオアデノシン、およびプトレシン。
Claims (8)
- 肺癌を検出するためのバイオマーカーパネルであって、ジアセチルスペルミン、C10:2、PC aa C32:2、PC ae C36:0、およびPC ae C44:5からなる血清バイオマーカーの群から選択される少なくとも1つの血清バイオマーカーを検出するバイオマーカーパネル。
- 前記血清バイオマーカーのうち少なくとも2つを検出する、請求項1に記載の肺癌を検出するためのバイオマーカーパネル。
- 前記血清バイオマーカーうちの少なくとも3つを検出する、請求項1に記載の肺癌を検出するためのバイオマーカーパネル。
- 前記血清バイオマーカーうちの少なくとも4つを検出する、請求項1に記載の肺癌を検出するためのバイオマーカーパネル。
- メチオニン、オルニチン、アルギニン、リソPCaC18:2、バリン、スペルミジン、およびスペルミンからなる血清バイオマーカーの群から選択される少なくとも1つの血清バイオマーカーをさらに検出する、請求項1に記載の肺癌を検出するためのバイオマーカーパネル。
- C5:1、C10:1、ADMA、C5-OH、SDMA、およびキヌレニンからなる尿バイオマーカーの群から選択される少なくとも1つの尿バイオマーカーをさらに検出する、請求項1に記載の肺癌を検出するためのバイオマーカーパネル。
- 肺癌を検出するためのバイオマーカーパネルであって、ジアセチルスペルミンを含む第1の血清バイオマーカーと、C10:2、PC aa C32:2、PC ae C36:0、PC ae C44:5、メチオニン、オルニチン、アルギニン、lysoPC a C18:2、バリン、スペルミジン、スペルミン、またはそれらの組み合わせからなる血清バイオマーカーの群から選択される少なくとも第2の血清バイオマーカーと、を検出するバイオマーカーパネル。
- C5:1、C10:1、ADMA、C5-OH、SDMA、およびキヌレニンからなる尿バイオマーカーの群から選択される少なくとも1つの尿バイオマーカーをさらに検出する、請求項7に記載の肺癌を検出するためのバイオマーカーパネル。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562185213P | 2015-06-26 | 2015-06-26 | |
US62/185,213 | 2015-06-26 | ||
PCT/CA2016/050758 WO2016205960A1 (en) | 2015-06-26 | 2016-06-27 | Method of detecting lung cancer |
JP2018518760A JP7038044B2 (ja) | 2015-06-26 | 2016-06-27 | 肺癌を検出するためのバイオマーカーパネル |
JP2022032288A JP7311659B2 (ja) | 2015-06-26 | 2022-03-03 | 肺癌を検出するためのバイオマーカーパネル |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022032288A Division JP7311659B2 (ja) | 2015-06-26 | 2022-03-03 | 肺癌を検出するためのバイオマーカーパネル |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2023126934A true JP2023126934A (ja) | 2023-09-12 |
Family
ID=57584379
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018518760A Active JP7038044B2 (ja) | 2015-06-26 | 2016-06-27 | 肺癌を検出するためのバイオマーカーパネル |
JP2022032288A Active JP7311659B2 (ja) | 2015-06-26 | 2022-03-03 | 肺癌を検出するためのバイオマーカーパネル |
JP2023111262A Pending JP2023126934A (ja) | 2015-06-26 | 2023-07-06 | 肺癌を検出するためのバイオマーカーパネル |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018518760A Active JP7038044B2 (ja) | 2015-06-26 | 2016-06-27 | 肺癌を検出するためのバイオマーカーパネル |
JP2022032288A Active JP7311659B2 (ja) | 2015-06-26 | 2022-03-03 | 肺癌を検出するためのバイオマーカーパネル |
Country Status (5)
Country | Link |
---|---|
US (1) | US11656229B2 (ja) |
JP (3) | JP7038044B2 (ja) |
CN (1) | CN108139381A (ja) |
CA (2) | CA3198282A1 (ja) |
WO (1) | WO2016205960A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117368475A (zh) * | 2017-02-09 | 2024-01-09 | 得克萨斯大学体系董事会 | 肺癌的检测和治疗方法 |
CA3124430A1 (en) | 2018-12-21 | 2020-06-25 | Biomark Cancer Systems Inc. | Method of detecting lung cancer |
WO2021016711A1 (en) * | 2019-07-29 | 2021-02-04 | Biomark Cancer Systems Inc. | Method of discriminating lung cancer patients |
US11840720B2 (en) | 2019-12-23 | 2023-12-12 | Metabolomic Technologies Inc. | Urinary metabolomic biomarkers for detecting colorectal cancer and polyps |
CN113960215B (zh) * | 2021-11-09 | 2024-03-26 | 上海市第一人民医院 | 用于肺腺癌诊断的标志物及其应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE555385T1 (de) | 2003-03-11 | 2012-05-15 | Crc Inc | N1,n12-diacetylspermin als tumormarker |
EP3153860A3 (en) | 2005-12-22 | 2017-06-14 | Abbott Molecular Inc. | Methods and marker combinations for screening for predisposition to lung cancer |
EP2405806A4 (en) | 2009-03-10 | 2014-01-22 | Univ Duke | PREDICTION OF CORONARY DISEASE AND THE RISK OF CARDIOVASCULAR EVENTS |
CN101806805A (zh) | 2010-03-16 | 2010-08-18 | 华中师范大学 | 一组用于肺癌患者的血清代谢生物标志物 |
WO2011128256A1 (en) | 2010-04-13 | 2011-10-20 | Universiteit Hasselt | Metabolic markers for diagnosing of cancer |
WO2012127984A1 (ja) | 2011-03-24 | 2012-09-27 | 学校法人慶應義塾 | 抗がん剤感受性の判定マーカー |
US20160041145A1 (en) | 2013-03-14 | 2016-02-11 | Biomarck Technologies Inc. | Detection And Quantification Of Acetylamantadine In Urine Samples |
CN103616450B (zh) | 2013-11-29 | 2015-12-30 | 湖州市中心医院 | 一种肺癌患者血清特异性代谢产物谱及其建立方法 |
CN104678002A (zh) | 2013-11-29 | 2015-06-03 | 沈阳药科大学 | 用于评估肺癌疾病的生物标记物 |
WO2015088947A1 (en) | 2013-12-09 | 2015-06-18 | Rush University Medical Center | Biomarkers of rapid progression in advanced non-small cell lung cancer |
-
2016
- 2016-06-27 CA CA3198282A patent/CA3198282A1/en active Pending
- 2016-06-27 CA CA3029063A patent/CA3029063C/en active Active
- 2016-06-27 WO PCT/CA2016/050758 patent/WO2016205960A1/en active Application Filing
- 2016-06-27 CN CN201680049414.0A patent/CN108139381A/zh active Pending
- 2016-06-27 US US15/739,608 patent/US11656229B2/en active Active
- 2016-06-27 JP JP2018518760A patent/JP7038044B2/ja active Active
-
2022
- 2022-03-03 JP JP2022032288A patent/JP7311659B2/ja active Active
-
2023
- 2023-07-06 JP JP2023111262A patent/JP2023126934A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3029063A1 (en) | 2016-12-29 |
WO2016205960A1 (en) | 2016-12-29 |
JP7311659B2 (ja) | 2023-07-19 |
JP2022071119A (ja) | 2022-05-13 |
US20180180618A1 (en) | 2018-06-28 |
CN108139381A (zh) | 2018-06-08 |
CA3029063C (en) | 2023-09-05 |
JP2018523139A (ja) | 2018-08-16 |
CA3198282A1 (en) | 2016-12-29 |
US11656229B2 (en) | 2023-05-23 |
JP7038044B2 (ja) | 2022-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7311659B2 (ja) | 肺癌を検出するためのバイオマーカーパネル | |
Wang et al. | Investigation and identification of potential biomarkers in human saliva for the early diagnosis of oral squamous cell carcinoma | |
US10768183B2 (en) | Metabolite panel for improved screening and diagnostic testing of cystic fibrosis | |
EP3546940B1 (en) | Biomarkers related to kidney function and methods using the same | |
CN112505228A (zh) | 用于评估受试者心血管疾病风险的代谢标志物组合及其应用 | |
WO2013177222A1 (en) | Metabolite biomarkers for the detection of liver cancer | |
EP3427064A1 (en) | Biomarker for the diagnosis of pulmonary hypertension (ph) | |
Wang et al. | Urinary metabolic profiling of colorectal carcinoma based on online affinity solid phase extraction-high performance liquid chromatography and ultra performance liquid chromatography-mass spectrometry | |
Chen et al. | Targeting amine-and phenol-containing metabolites in urine by dansylation isotope labeling and liquid chromatography mass spectrometry for evaluation of bladder cancer biomarkers | |
KR101806136B1 (ko) | 대사체 분석을 이용한 베체트병 관절염의 진단방법 | |
Joshi et al. | Recent progress in mass spectrometry-based urinary proteomics | |
US20230251261A1 (en) | Method of detecting lung cancer | |
EP3265828A1 (en) | Methods and systems for measuring serotonin in a sample | |
US20220003769A1 (en) | Method Of Detecting Lung Cancer | |
US20220260573A1 (en) | Method of discriminating lung cancer patients | |
Chen et al. | Simultaneous determination of urinary quinolinate, gentisate, 4-hydroxybenzoate, and α-ketoglutarate by high-performance liquid chromatography-tandem mass spectrometry | |
JPWO2013038739A1 (ja) | 肺癌マーカー補体C3dg分子及び肺癌マーカーの分析方法 | |
KR20210130970A (ko) | 간암 진단용 조성물 및 이를 포함하는 키트 | |
CN115023609A (zh) | 早期非小细胞肺癌的诊断方法 | |
WO2019013256A1 (ja) | 生物学的検体の品質評価方法およびそのためのマーカー | |
Reddy et al. | Basics of Mass Spectrometry and Its Applications in Biomarker Discovery | |
Collino et al. | Metabonomics in clinical practice | |
CA2875331A1 (en) | Methods for diagnosing chronic valvular disease | |
Halifax | MSACL 2023 Abstract (s) for Assays Leveraging MS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230802 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20230905 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20230906 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240514 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240515 |